News

US drug reviewers have questioned a Genzyme study meant to back wider use of the Clolar leukemia drug. Clolar is approved for treating a type of leukemia in

Mylan has announced that its subsidiary Matrix Laboratories has been notified by the World Health Organization (WHO) Prequalification of Medicines Programme that the WHO has withdrawn its notice

Boehringer Ingelheim has revealed that the new analysis of the UPLIFT trial, shows that tiotropium administered to Chronic Obstructive Pulmonary Disease (COPD) patients with moderate disease severity produced

Orexo has signed an exclusive worldwide licensing agreement with Novartis to develop and commercialise a novel product related to Orexo’s OX17 program. Under the terms of the agreement,

BTG has announced the sale of HySolv drug delivery technology to Novartis Pharma for an initial payment of $0.75m and potential additional future milestone payments of up to

Takeda Pharmaceutical and Takeda Global Research & Development Center have announed that the latter has received notification, that the FDA has agreed to the study design for a

Eurand has received FDA approval of its New Drug Application (NDA) for ZENPEP (pancrelipase) delayed-release Capsules for the treatment of exocrine pancreatic insufficiency (EPI) in patients with cystic

Hisamitsu has reported that the subsequent Offering Period set forth for the shareholders of Noven has not tendered its shares before the end of the period of the

Novartis India has launched Otrivin in a Nasal Spray format. Otrivin will now be available as a topical nasal decongestant in an easy-to-use direct acting spray format in